A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

Prior treatment

• Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose of trial intervention or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial
• Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM
• Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids

Other illness

• Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients

Age

• Myeloma Frailty Score of greater than or equal to (\>=) 2 with the exception of participants who have a score of 2 based on age alone

• Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria
• Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT
• Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2
• Must sign an informed consent form (ICF)
• Measurable disease at screening as assessed by central laboratory as defined in the protocol